Effects of Dose Modifications on the Safety and Efficacy of Dacomitinib for EGFR Mutation-Positive NSCLC

被引：5

作者：

Mok, T. ^{[1
]}

Nakagawa, K. ^{[2
]}

Rosell, R. ^{[3
]}

Lee, K. ^{[4
]}

Corral, J. ^{[5
]}

Migliorino, M. R. ^{[6
]}

Pluzanski, A. ^{[7
]}

Linke, R. ^{[8
]}

Devgan, G. ^{[9
]}

Sbar, E. ^{[10
]}

Quinn, S. ^{[11
]}

Wang, T. ^{[11
]}

Wu, Y. ^{[12
,13
]}

机构：

[1] Chinese Univ Hong Kong, Hong Kong, Peoples R China

[2] Kindai Univ Hosp, Osaka, Japan

[3] Catalan Inst Oncol, Barcelona, Spain

[4] Chungbuk Natl Univ Hosp, Cheongju, South Korea

[5] Hosp Univ Virgen Del Rocio, Seville, Spain

[6] San Camillo Forlanini Hosp, Pulm Oncol Unit, Rome, Italy

[7] Maria Sklodowska Curie Mem Canc Ctr & Inst Oncol, Warsaw, Poland

[8] Sfj Pharmaceut Grp, Pleasanton, CA USA

[9] Pfizer Oncol, New York, NY USA

[10] Pfizer Oncol, Collegeville, PA USA

[11] Pfizer Oncol, Cambridge, MA USA

[12] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China

[13] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China

来源：

关键词：

dose reduction; non-small cell lung cancer; Dacomitinib;

D O I：

10.1016/j.jtho.2018.08.546

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA26.11

引用

页码：S454 / S454

页数：1